Teva Pharmaceutical (TEVA) and Alvotech (ALVO) said Monday that Selarsdi has been approved by the US Food and Drug administration as interchangeable with the reference biologic Stelara.
Selarsdi, a human monoclonal antibody that selectively targets the p40 protein, is now interchangeable in all presentations of Stelara, which includes the treatment of psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis, the two companies said.
Teva shares were more than 7% higher in premarket trading, while Alvotech shares rose by nearly 2%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。